Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Liu, Xiuying ^a   Chi, Xiumei ^b   Gong, Qiaoling ^a   Gao, Lei ^a   Niu, Yuqiang ^a   Chi, Xiaojing ^a   Cheng, Min ^a   Si, Youhui ^a   Wang, Maorong ^c   Zhong, Jin ^d   Niu, Junqi ^b   Yang, Wei ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b JILIN UNIVERSITY   (China)

^c PLA Cancer Center   (China)

^d INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; GROWTH DIFFERENTIATION FACTOR 15; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS C; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; MYCOBACTERIUM TUBERCULOSIS;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84930633673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127518     Document Type: Article

References (37)

1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009; 3(4):353-67. PMID: 19673623. doi: 10.1586/egh.09.35
2. D'Ippolito G, Torres LR, Saito Filho CF, Ferreira RM. CT and MRI in monitoring response: state-of-theart and future developments. Q J Nucl Med Mol Imaging. 2011; 55(6):603-19. PMID: 22231581.
3. Alisi A, de Vito R, Monti L, Nobili V. Liver fibrosis in paediatric liver diseases. Best Pract Res Clin Gastroenterol. 2011; 25(2):259-68. PMID: 21497743. doi: 10.1016/j.bpg.2011.02.008
4. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005; 43(3):434-41. PMID: 16136646.
5. Ezaki T, Yukaya H, Ogawa Y, Chang YC, Nagasue N. Elevation of alpha-fetoprotein level without evidence of recurrence after hepatectomy for hepatocellular carcinoma. Cancer. 1988; 61(9):1880-3. PMID: 2451558.
6. Si Y, Liu X, Cheng M, Wang M, Gong Q, Yang Y, et al. Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes. PLoS One. 2011; 6(5):e19967. PMID: 21625435; PubMed Central PMCID: PMC3100307. doi: 10.1371/journal.pone.0019967
7. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997; 94(21):11514-9. PMID: 9326641; PubMed Central PMCID: PMC23523.
8. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther. 2003; 2(10):1023-9. PMID: 14578467.
9. Yamaguchi K, Lee SH, Eling TE, Baek SJ. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem. 2004; 279(48):49617-23. PMID: 15377673.
10. Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem. 2005; 280(19):18636-42. PMID: 15757899.
11. Qian Y, Jung YS, Chen X. DEC1 and MIC-1: new players of p53-dependent cell fate decision. Cell Cycle. 2012; 11(19):3525-6. PMID: 22935706; PubMed Central PMCID: PMC3478296. doi: 10.4161/cc.21962
12. Qian Y, Jung YS, Chen X. Differentiated embryo-chondrocyte expressed gene 1 regulates p53-dependent cell survival versus cell death through macrophage inhibitory cytokine-1. Proc Natl Acad Sci U S A. 2012; 109(28):11300-5. PMID: 22723347; PubMed Central PMCID: PMC3396538. doi: 10.1073/pnas.1203185109
13. Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG, et al. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J. 2000; 19(10):2212-20. PMID: 10811612; PubMed Central PMCID: PMC384362.
14. Subramaniam S, Strelau J, Unsicker K. Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem. 2003; 278(11):8904-12. PMID: 12514175.
15. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006; 66(10):4983-6. PMID: 16707416.
16. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, Zheng SL, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res. 2009; 15(21):6658-64. PMID: 19843661; PubMed Central PMCID: PMC3557964. doi: 10.1158/1078-0432.CCR-08-3126
17. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res. 2006; 12(1):89-96. PMID: 16397029.
18. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003; 9(7):2642-50. PMID: 12855642.
19. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004; 10(7):2386-92. PMID: 15073115.
20. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006; 12(2):442-6. PMID: 16428484.
21. Kadara H, Schroeder CP, Lotan D, Pisano C, Lotan R. Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of its role in apoptosis. Cancer Biol Ther. 2006; 5(5):518-22. PMID: 16582595.
22. Suesskind D, Schatz A, Schnichels S, Coupland SE, Lake SL, Wissinger B, et al. GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol. 2012; 250(6):887-95. PMID: 21881845. doi: 10.1007/s00417-011-1786-6
23. Yamashita T, Yoneta A, Hida T. Macrophage inhibitory cytokine-1: a new player in melanoma development. J Invest Dermatol. 2009; 129(2):262-4. PMID: 19148214. doi: 10.1038/jid.2008.366
24. Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet RJ Jr., Mehrotra S, et al. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis. 2005; 26(5):900-7. PMID: 15677629.
25. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002; 359(9324):2159-63. PMID: 12090982.
26. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin. 2009; 5(4):537-47. PMID: 19631178. doi: 10.1016/j.hfc.2009.04.006
27. Montoro-Garcia S, Hernandez-Romero D, Jover E, Garcia-Honrubia A, Vilchez JA, Casas T, et al. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med. 2012; 23(2):169-74. PMID: 22284249. doi: 10.1016/j.ejim.2011.08.022
28. Hellemons ME, Mazagova M, Gansevoort RT, Henning RH, de Zeeuw D, Bakker SJ, et al. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care. 2012; 35(11):2340-6. PMID: 22815297; PubMed Central PMCID: PMC3476892. doi: 10.2337/dc12-0180
29. Tsai VW, Macia L, Johnen H, Kuffner T, Manadhar R, Jorgensen SB, et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One. 2013; 8(2):e55174. PMID: 23468844; PubMed Central PMCID: PMC3585300. doi: 10.1371/journal.pone.0055174
30. Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, et al. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology. 2012; 56(2):507-15. PMID: 22378192; PubMed Central PMCID: PMC3406249. doi: 10.1002/hep.25685
31. Songsivilai S, Dharakul T, Senawong S. Hepatitis B- and hepatitis C-associated hepatocellular carcinoma: evaluation of alpha-fetoprotein as a diagnostic marker. Asian Pac J Allergy Immunol. 1995; 13(2):167-71. PMID: 8703246.
32. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007; 115(8):962-71. PMID: 17283261.
33. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010; 122(14):1387-95. doi: 10.1161/CIRCULATIONAHA.109.928846 CIRCULATIONAHA.109.928846 [pii]. PMID: 20855664.
34. Attallah AM, Shiha GE, Ismail H, Mansy SE, El-Sherbiny R, El-Dosoky I. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem. 2009; 42(6):455-61. PMID: 19063876. doi: 10.1016/j.clinbiochem.2008.11.004
35. Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med. 2009; 7:110. PMID: 20025780; PubMed Central PMCID: PMC2809055. doi: 10.1186/1479-5876-7-110
36. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis. 2002; 23(3):425-34. PMID: 11895857.
37. Zimmers TA, Jin X, Gutierrez JC, Acosta C, McKillop IH, Pierce RH, et al. Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis. J Cancer Res Clin Oncol. 2008; 134(7):753-9. PMID: 18210153. doi: 10.1007/s00432-007-0336-4